Arrowhead Pharmaceuticals Overview
- Founded
-
1989

- Status
-
Public
- Employees
-
397

- Stock Symbol
-
ARWR

- Investments
-
11
- Share Price
-
$33.28
- (As of Monday Closing)
Arrowhead Pharmaceuticals General Information
Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Contact Information
- 177 East Colorado Boulevard
- Suite 700
- Pasadena, CA 91105
- United States
Arrowhead Pharmaceuticals Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$33.28 | $33.61 | $26.81 - $56.25 | $3.79B | 114M | 1.01M | -$1.67 |
Arrowhead Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 30-Sep-2022 | FY 2021 30-Sep-2021 | FY 2020 30-Sep-2020 |
---|---|---|---|---|
EV | 3,183,176 | 3,183,176 | 6,016,737 | 4,138,470 |
Revenue | 243,231 | 243,231 | 138,287 | 87,992 |
EBITDA | (167,321) | (167,321) | (138,699) | (87,800) |
Net Income | (176,063) | (176,063) | (140,848) | (84,553) |
Total Assets | 691,939 | 691,939 | 710,148 | 522,504 |
Total Debt | 81,576 | 81,576 | 25,545 | 21,138 |
Arrowhead Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Arrowhead Pharmaceuticals Comparisons
Industry
Financing
Details
Arrowhead Pharmaceuticals Competitors (87)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
00000 000000000000 | Corporate Backed or Acquired | Carlsbad, CA | 000 | 0000 | 00000000000 | 0000 |
0000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
00000000 000000000 | Formerly VC-backed | Waltham, MA | 00 | 00000 | 00000000 | 00000 |
Arrowhead Pharmaceuticals Patents
Arrowhead Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230013224-A1 | Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use | Pending | 21-Jun-2021 | 00000000000 | |
US-20230002773-A1 | Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use | Active | 21-Jun-2021 | 00000000000 | |
US-11549112-B1 | Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use | Active | 21-Jun-2021 | 00000000000 | 00 |
US-20230002767-A1 | Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use | Pending | 28-May-2021 | 0000000000 | |
US-20220396791-A1 | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | Pending | 08-Apr-2021 | C12N15/1138 |
Arrowhead Pharmaceuticals Executive Team (16)
Arrowhead Pharmaceuticals Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
000000 00000000 00 | Self | Board Member | 000 0000 |
00000000000 000000 | Arrowhead Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
00000000 00000 00 | Self | Chairman & Board Member | 000 0000 |
00000000 00 000000 | Self | Board Member | 000 0000 |
00000 0000000 00.0 | Self | Board Member | 000 0000 |
Arrowhead Pharmaceuticals Signals
Arrowhead Pharmaceuticals Investments & Acquisitions (11)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 29-Apr-2022 | 00000 0000 | 0000 | Drug Discovery | |
0000000(00000 | 25-Apr-2022 | 00000 0000 | 0000 | Drug Discovery | |
00000000 (000 | 05-Mar-2015 | 0000000000 | 0000 | Biotechnology | 000000000 |
00000 0000000 | 11-Apr-2012 | 0000000000 | 000 | Drug Discovery | |
Roche Holding (RNA Therapeutics Business) | 24-Oct-2011 | Merger/Acquisition | 00.00 | Drug Delivery | 000000000 |
Arrowhead Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 14, 2022
25.06 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,004
Rank
Percentile

Biotechnology
Subindustry
00 of 462
Rank
Percentile

Arrowhead Pharmaceuticals Exits (5)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
000000 | 01-Aug-2008 | 000000000000000000 | 00000 | Completed |
|
000000 | 17-Jun-2008 | 00000 00000 00 | 000 | Completed |
|
0000000 0000000000 | 16-Oct-2006 | 00000 00000 00 | 000.00 | Completed |
|
0000000 0000000000 | 04-Jun-2004 | 000000000000000000 | Completed |
|
|
Unidym | Early Stage VC | 000 | Completed |